Medtronic beats Boston Scientific in drug-eluting stent studies

Medtronic's Resolute drug-eluting stent beat out rival Boston Scientific's Taxus DES in late lumen loss after 8 months in a study that helps pave the way for Japanese regulatory approval for Resolute. In the language of drug-eluting stents, "late lumen loss" is the difference in millimeters between a stent just after the procedure and again after 6 to 9 months. Some loss in diameter of the stent is inevitable as tissue grows in, but there needs to be enough tissue suppression to that there is no further narrowing of a blood vessel. More here

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.